Invests $446000 in Clovis Oncology, Inc. (CLVS)

James Marshall
July 29, 2017

06/22/2017 - Oppenheimer began new coverage on Clovis Oncology, Inc. giving the company a " rating. It fall, as 30 investors sold Clovis Oncology Inc shares while 48 reduced holdings. It has outperformed by 266.01% the S&P500.The move comes after 7 months positive chart setup for the $4.39B company.

German American Bancorp Incorporated (NASDAQ:GABC) had an increase of 11.9% in short interest. IOTS's SI was 227,700 shares in July as released by FINRA. Its up 11.9% from 1.07 million shares previously. The SI to German American Bancorp Incorporated's float is 8.63%. About 54,210 shares traded. Lendingtree Inc (TREE) has risen 126.83% since July 27, 2016 and is uptrending. It has outperformed by 31.03% the S&P500.

Since March 15, 2017, it had 0 insider purchases, and 3 selling transactions for $528,600 activity. Tcw Group Inc acquired 7,063 shares as Ross Stores Inc (ROST)'s stock declined 9.26%. Credit Suisse Ag owns 134,988 shares. The insider SEGER THOMAS W bought $1,410. BUSH MICHAEL J sold $493,883 worth of Ross Stores, Inc. Eight analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has market cap of $2.59 billion. (NASDAQ:ROST) has "Outperform" rating given on Thursday, October 22 by Wells Fargo. The firm has "Hold" rating given on Wednesday, July 5 by BMO Capital Markets. The company was maintained on Friday, February 26 by Stifel Nicolaus. The firm earned "Neutral" rating on Tuesday, December 20 by Chardan Capital Markets.

German American Bancorp, Inc.is a bank holding company. The company has market cap of $99.54 million. As of December 31, 2016, the Company, through its banking subsidiary German American Bancorp, operated 51 banking offices in 19 contiguous southern in counties and one northern Kentucky county. It has a 21.49 P/E ratio.

Investors sentiment decreased to 1.03 in 2016 Q4. Its down 0.97, from 2 in 2016Q3. Institutional investors and hedge funds own 89.61% of the company's stock. 38 funds opened positions while 42 raised stakes. Alliancebernstein Limited Partnership owns 18,400 shares. ValuEngine raised shares of Clovis Oncology from a sell rating to a hold rating in a report on Friday, June 2nd.

WARNING: This article was first published by BNB Daily and is the property of of BNB Daily. Over the last five days, shares have managed 8.19% gains and now is up 64.7% since hitting its 200-day moving average of $65.06. Zooming out to the 50-day, we can see that shares are now trading -0.46% off of that mark. Wellington Management Gru Ltd Liability Partnership has invested 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Moreover, Carroll Financial Associates has 0% invested in Safestyle UK PLC (LON:SFE) for 1,000 shares. Zooming out to the 50-day, we can see that shares are now trading 21.15% off of that mark. Us Bank De holds 0% or 23,200 shares. Northern Trust Corporation reported 421,756 shares. (NASDAQ:GABC). 672,398 were reported by Fmr Limited Co. Lord Abbett & Communications Limited Liability Co holds 199,373 shares or 0.03% of its portfolio. Acadian Asset Management LLC claims 43 shares worth $4,000. Ny State Common Retirement Fund has 39,782 shares for 0% of their portfolio.

State Street Corp lowered its position in shares of Clovis Oncology, Inc. Therefore 67% are positive. The analysts estimated sales for the higher end at 27 million and lower end at 10.6 million while the year ago reported sale was 4.44 million. The firm earned "Buy" rating on Monday, November 9 by N+1 Singer. The firm has "Neutral" rating given on Tuesday, November 17 by Goldman Sachs. The rating was maintained by Liberum Capital on Wednesday, August 12 with "Buy". As per Wednesday, May 17, the company rating was upgraded by JP Morgan. As per Monday, January 25, the company rating was maintained by Mizuho. (NASDAQ:CLVS) opened at 92.25 on Friday. Piper Jaffray reinitiated the shares of CLVS in report on Monday, April 4 with "Neutral" rating. The firm has "Buy" rating given on Thursday, September 15 by Liberum Capital. (NASDAQ:ROST) rating on Friday, August 19. The current share price indicates that stock is -4.82% away from its one year high and is moving 572.87% ahead of its 52-week low. Analysts forecast that Clovis Oncology, Inc. will post ($5.62) earnings per share for the current year. They expect $-1.29 EPS, up 37.68% or $0.78 from last year's $-2.07 per share.

The share price of the company (NASDAQ:CLVS) was up +5.51% during the last trading session, with a high of 93.81 and the volume of Clovis Oncology, Inc. shares traded was 2679482.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER